Do analysts rate BFRI or TENX?

Tenax Therapeutics has a consensus price target of $14.00, indicating a potential upside of 636.84%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tenax Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.40

Does the media prefer BFRI or TENX?

In the previous week, Tenax Therapeutics had 4 more articles in the media than Biofrontera. MarketBeat recorded 9 mentions for Tenax Therapeutics and 5 mentions for Biofrontera. Tenax Therapeutics' average media sentiment score of 1.51 beat Biofrontera's score of 0.66 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate LONA or BFRI?

Athira Pharma presently has a consensus target price of $17.33, suggesting a potential upside of 155.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Athira Pharma is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LONA or BFRI more profitable?

Athira Pharma has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% Biofrontera -13.78% -145.81% -31.30%

Do analysts prefer SPRO or BFRI?

Spero Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 430.97%. Given Spero Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Spero Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to SPRO or BFRI?

In the previous week, Spero Therapeutics had 5 more articles in the media than Biofrontera. MarketBeat recorded 10 mentions for Spero Therapeutics and 5 mentions for Biofrontera. Spero Therapeutics' average media sentiment score of 1.16 beat Biofrontera's score of 0.66 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biofrontera 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZYBT or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, ZYBT or BFRI?

Zhengye Biotechnology has higher earnings, but lower revenue than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 3.90 -$9.98M N/A N/A Biofrontera $41.71M 0.47 -$10.54M -$0.45 N/A

Do analysts recommend BFRI or ATHE?

Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 155.75%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has stronger valuation & earnings, BFRI or ATHE?

Biofrontera has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $41.71M 0.47 -$10.54M -$0.45 N/A Alterity Therapeutics N/A N/A -$15.88M N/A N/A

Does the media refer more to BFRI or ATHE?

In the previous week, Biofrontera had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Biofrontera and 2 mentions for Alterity Therapeutics. Biofrontera's average media sentiment score of 0.66 beat Alterity Therapeutics' score of 0.33 indicating that Biofrontera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biofrontera (BFRI) Competitors

$1.32 +0.08 (+6.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.31 -0.01 (-0.98%)

As of 09/18/2026 07:58 PM Eastern

Compare

BFRI vs. TENX, LONA, SPRO, ZYBT, and ATHE

Should you buy Biofrontera stock or one of its competitors? Biofrontera's main competitors and comparable companies include Tenax Therapeutics (TENX), Athira Pharma (LONA), Spero Therapeutics (SPRO), Zhengye Biotechnology (ZYBT), and Alterity Therapeutics (ATHE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biofrontera compare to Tenax Therapeutics?

Biofrontera (NASDAQ:BFRI) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tenax Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Tenax Therapeutics' return on equity of -61.54% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Tenax Therapeutics has a consensus price target of $14.00, indicating a potential upside of 636.84%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Tenax Therapeutics had 4 more articles in the media than Biofrontera. MarketBeat recorded 9 mentions for Tenax Therapeutics and 5 mentions for Biofrontera. Tenax Therapeutics' average media sentiment score of 1.51 beat Biofrontera's score of 0.66 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biofrontera has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Biofrontera has higher revenue and earnings than Tenax Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.47	-$10.54M	-$0.45	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Summary

Tenax Therapeutics beats Biofrontera on 10 of the 15 factors compared between the two stocks.

How does Biofrontera compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Biofrontera has higher revenue and earnings than Athira Pharma. Biofrontera is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Biofrontera	$41.71M	0.47	-$10.54M	-$0.45	N/A

Athira Pharma has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Biofrontera	-13.78%	-145.81%	-31.30%

Athira Pharma presently has a consensus target price of $17.33, suggesting a potential upside of 155.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Athira Pharma is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Athira Pharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

In the previous week, Biofrontera had 5 more articles in the media than Athira Pharma. MarketBeat recorded 5 mentions for Biofrontera and 0 mentions for Athira Pharma. Biofrontera's average media sentiment score of 0.66 beat Athira Pharma's score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
Athira Pharma	Neutral
Biofrontera	Positive

Summary

Athira Pharma beats Biofrontera on 8 of the 15 factors compared between the two stocks.

How does Biofrontera compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Spero Therapeutics has higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	0.99	$8.57M	$0.11	10.27
Biofrontera	$41.71M	0.47	-$10.54M	-$0.45	N/A

In the previous week, Spero Therapeutics had 5 more articles in the media than Biofrontera. MarketBeat recorded 10 mentions for Spero Therapeutics and 5 mentions for Biofrontera. Spero Therapeutics' average media sentiment score of 1.16 beat Biofrontera's score of 0.66 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biofrontera	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 8.1% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spero Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Spero Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 430.97%. Given Spero Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Spero Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Spero Therapeutics has a net margin of 24.90% compared to Biofrontera's net margin of -13.78%. Spero Therapeutics' return on equity of 16.17% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
Biofrontera	-13.78%	-145.81%	-31.30%

Summary

Spero Therapeutics beats Biofrontera on 14 of the 15 factors compared between the two stocks.

How does Biofrontera compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Zhengye Biotechnology has a beta of -2.56, indicating that its stock price is 356% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Zhengye Biotechnology has higher earnings, but lower revenue than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	3.90	-$9.98M	N/A	N/A
Biofrontera	$41.71M	0.47	-$10.54M	-$0.45	N/A

Zhengye Biotechnology has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Zhengye Biotechnology's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Biofrontera	-13.78%	-145.81%	-31.30%

10.1% of Biofrontera shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Biofrontera had 5 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Biofrontera and 0 mentions for Zhengye Biotechnology. Biofrontera's average media sentiment score of 0.66 beat Zhengye Biotechnology's score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Biofrontera	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Biofrontera beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Biofrontera compare to Alterity Therapeutics?

Biofrontera (NASDAQ:BFRI) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Alterity Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Alterity Therapeutics' return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Alterity Therapeutics	N/A	N/A	N/A

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Biofrontera has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.47	-$10.54M	-$0.45	N/A
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A

In the previous week, Biofrontera had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Biofrontera and 2 mentions for Alterity Therapeutics. Biofrontera's average media sentiment score of 0.66 beat Alterity Therapeutics' score of 0.33 indicating that Biofrontera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 155.75%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Alterity Therapeutics beats Biofrontera on 7 of the 13 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRI vs. The Competition

Export

Metric	Biofrontera	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.60M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-2.93	797.25	275.49	25.40
Price / Sales	0.47	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	1.47	10.53	10.46	6.33
Net Income	-$10.54M	$2.82B	$3.49B	$358.33M
7 Day Performance	-14.84%	1.69%	0.59%	1.12%
1 Month Performance	-10.81%	0.24%	-1.74%	-2.39%
1 Year Performance	46.67%	3.95%	18.13%	5.35%

Biofrontera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRI Biofrontera	1.2234 of 5 stars	$1.32 +6.5%	N/A	+46.7%	$19.60M	$41.71M	N/A	94	News Coverage Analyst Downgrade
TENX Tenax Therapeutics	4.0387 of 5 stars	$1.82 -0.5%	$14.00 +669.2%	-70.4%	$68.49M	N/A	N/A	16	Positive News Insider Trade Short Interest Increase Gap Up
LONA Athira Pharma	2.3457 of 5 stars	$6.79 -6.2%	$17.33 +155.3%	N/A	$68.01M	N/A	N/A	19	Gap Up
SPRO Spero Therapeutics	4.1015 of 5 stars	$1.11 -1.8%	$6.00 +440.5%	-43.5%	$65.81M	$66.80M	10.09	150	Positive News Analyst Revision
ZYBT Zhengye Biotechnology	N/A	$1.37 -0.7%	N/A	-85.2%	$65.40M	$16.64M	N/A	269

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRI) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biofrontera (BFRI) Competitors

BFRI vs. TENX, LONA, SPRO, ZYBT, and ATHE

How does Biofrontera compare to Tenax Therapeutics?

Summary

How does Biofrontera compare to Athira Pharma?

Summary

How does Biofrontera compare to Spero Therapeutics?

Summary

How does Biofrontera compare to Zhengye Biotechnology?

Summary

How does Biofrontera compare to Alterity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biofrontera (BFRI) Competitors

BFRI vs. TENX, LONA, SPRO, ZYBT, and ATHE

How does Biofrontera compare to Tenax Therapeutics?

Do insiders & institutionals believe in BFRI or TENX?

Is BFRI or TENX more profitable?

Do analysts rate BFRI or TENX?

Does the media prefer BFRI or TENX?

Which has more volatility and risk, BFRI or TENX?

Which has higher valuation and earnings, BFRI or TENX?

Summary

How does Biofrontera compare to Athira Pharma?

Do insiders and institutionals believe in LONA or BFRI?

Which has better valuation and earnings, LONA or BFRI?

Is LONA or BFRI more profitable?

Do analysts rate LONA or BFRI?

Which has more volatility & risk, LONA or BFRI?

Does the media refer more to LONA or BFRI?

Summary

How does Biofrontera compare to Spero Therapeutics?

Which has better earnings and valuation, SPRO or BFRI?

Does the media refer more to SPRO or BFRI?

Do insiders & institutionals hold more shares of SPRO or BFRI?

Which has more risk & volatility, SPRO or BFRI?

Do analysts prefer SPRO or BFRI?

Is SPRO or BFRI more profitable?

Summary

How does Biofrontera compare to Zhengye Biotechnology?

Which has more risk & volatility, ZYBT or BFRI?

Which has higher valuation & earnings, ZYBT or BFRI?

Is ZYBT or BFRI more profitable?

Do insiders and institutionals hold more shares of ZYBT or BFRI?

Does the media favor ZYBT or BFRI?

Do analysts rate ZYBT or BFRI?

Summary

How does Biofrontera compare to Alterity Therapeutics?

Is BFRI or ATHE more profitable?

Do insiders and institutionals have more ownership in BFRI or ATHE?

Which has more volatility and risk, BFRI or ATHE?

Which has stronger valuation & earnings, BFRI or ATHE?

Does the media refer more to BFRI or ATHE?

Do analysts recommend BFRI or ATHE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools